濮阳市东方医院技术权威(濮阳东方医院男科割包皮价格不高) (今日更新中)

SAN FRANCISCO, June 14 (Xinhua) -- Google on Tuesday introduced several new features of its search services on desktops and smartphones, which the Internet search giant said could help users get to their search results faster.SEARCH BY VOICE, IMAGESpeaking at Google's Inside Search event in San Francisco, Mike Cohen, head of the company's speech technology efforts, said its voice search is now available in 27 languages and dialects, an estimated coverage of around 5 billion people or two-thirds of world population.Voice search has already been available in Google's mobile search application from 2008. Adding the feature to desktops is part of Google's strategy to bring mobile innovations to its desktop search.The voice search on desktop performs similarly to voice search on smartphones -- users can click the microphone button and speak the query. It is only available via Google's Chrome browser for now.Cohen noted that the volume of Google mobile speech inputs has increased by six times in the last year.Also at the event, Google introduced search-by-image, which enables users to drag-and-drop, copy-and-paste image URL, or upload the image from the desktop into the search box. They can also use a Chrome or FireFox software extension to add images to the search.Google said the search-by-image feature will be available in most countries and regions over the next few days to Chrome users, noting that it will not collect and store any images that users use.

NANCHANG, Aug. 12 (Xinhua) -- Seventy-seven people were hospitalized after eating lobsters in a city in east China's Jiangxi Province, local authorities said Friday.The residents of the city of Ruichang suffered vomiting and diarrhea after attending a lobster feast Thursday night. The hospitalized residents are all in stable condition.It is believed that the diners might have been sickened by E. coli contamination, according to doctors at the Ruichang People's Hospital.Local authorities are continuing to investigate the case. Citizens suffering from diarrhoea or vomiting receive medical treatment in a hospital in Ruichang City, east China's Jiangxi Province, Aug. 12, 2011

NEW YORK, July 15 (Xinhua) -- A Gallup survey released on Friday found a total of 59 percent of Americans support a ban on smoking in all public places.The July 7-10 survey among 1,016 national adults showed a change in the public's attitude toward public smoking ban. In 2001, when Gallup first asked about a ban on public smoking, 39 percent were in favor, an attitude that stayed roughly the same through 2007.At the same time, the poll also found that fewer than two in 10 people supported the idea of making smoking totally illegal.According to the American Lung Association, 27 states plus the District of Columbia have passed comprehensive smoke-free laws. A New York City law bans smoking in virtually all public places, including outdoor plazas and beaches.

SYDNEY, Aug. 5 (Xinhua) -- The Western Australian Government announced on Friday that 14 new substances linked to the manufacture of the synthetic drug Kronic would be banned from Friday midnight.The State Mental Health Minister Helen Morton told the Australian Broadcasting Corporation (ABC) Radio on Friday morning that two substances found in Kronic Black would be banned from midnight tonight (Friday night), as well as another 12 others found in synthetic cannabis products.People caught in possession of banned synthetic cannabis face hefty fines or possible jail sentences.The government of Western Australia (WA) in June listed a number of synthetic cannabis products, including Kronic, Voodoo and Mango Kush, as illegal substances.But synthetic drug makers have since released a new product, Kronic Black Label, using a different blend of chemicals they say make it still legal to sell.Police suspect the death of a 38-year-old Perth man is linked to his smoking of the synthetic cannabis product Kronic Black Label, which contains two of the 14 substances to be banned.The man, from Hillman in Perth's south, was rushed to Rockingham Hospital on Thursday night after suffering a suspected cardiac arrest, but he later died.Police now are conducting an investigation to identify the cause of the man's death.The Australian Medical Association has warned that synthetic drugs could cause severe paranoia, anxiety and panic attacks.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

来源：资阳报